CARMOT THERAPEUTICS, INC.

Basic Information

409 ILLINOIS ST
SAN FRANCISCO, CA, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 828863022
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of

    Amount: $1,911,764.00

    DESCRIPTION: Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of cancer Project Summary/Abstract Protein-protein interactions represent the largest untapped opportunity f ...

    SBIR Phase II 2013 Department of Health and Human Services
  2. Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o

    Amount: $541,527.00

    DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the most challenging health problems of the 21st century. Global health care expenditures to treat diabetes and its complication ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. A novel approach to discover selective small molecule inhibitors of FABP4 and FAB

    Amount: $299,807.00

    DESCRIPTION (provided by applicant): A novel approach to discover selective small molecule inhibitors of FABP4 and FABP5 for the treatment of metabolic diseases The Western diet and lifestyle has brou ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Discovery of small molecule drug candidates that disrupt the NEMO/IKK signaling c

    Amount: $299,307.00

    DESCRIPTION (provided by applicant): Protein-protein interactions represent the largest untapped opportunity for therapeutic development. The number of protein-protein interactions in human cells has ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government